Orion Biotechnology Publishes White-paper Highlighting the Importance and Challenges in Unlocking “Undruggable” GPCRs
February 02, 2023 10:07 ET | Source: Orion Biotechnology Canada Ltd.
Ottawa, Canada, Feb. 02, 2023 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it has published a new whitepaper detailing the importance of GPCRs and challenges in unlocking these important but inadequately drugged targets. Available on Fierce Biotech and Dr. GPCR, Orion’s whitepaper reviews the complexities of GPCRs and describes their role as premier drug targets. Additionally, the whitepaper includes a case study summarizing Orion’s new approach for effectively targeting small protein GPCRs.
Commenting on Orion’s whitepaper, Dr. Oliver Hartley (VP Drug Discovery) said: “Our intention is to provide a thorough background on small protein GPCRs, while illuminating the need for a specialized approach to drug discovery. Therefore, this whitepaper will also elucidate the role of precision-engineered small protein ligand analogs as potent modulators of small protein GPCRs.”
Similarly, Orion’s CEO Mark Groper remarked: “Despite their potential to deliver transformative new medicines, the vast majority of small protein GPCRs have proven to be “undruggable” using traditional drug discovery techniques. Orion’s PROcisionXTM platform enables a new approach to effectively and rapidly target these important receptors. Our aim with this whitepaper is to provide readers with a deeper understanding of Orion’s new approach to unlocking these important but inadequately drugged targets.”
Original Publication:https://www.globenewswire.com/en/news-release/2023/02/02/2600658/0/en/Orion-Biotechnology-Publishes-Whitepaper-Highlighting-the-Importance-and-Challenges-in-Unlocking-Undruggable-GPCRs.html
Recent Posts
- Ground-Breaking, Drug-Free, and Clinically Tested BackVive Patch Offers Long-Lasting Relief to Chronic Back Pain Sufferers
- SWIR Vision Systems Announces Acuros GO 6 MP Handheld SWIR Camera
- LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD)
- SWIR Vision Systems Secures Direct to Phase II SBIR Award for Low-Cost SWIR ALPD Technology
- SWIR Vision Systems Unveils 6.3 MP and 4.2 MP Short Wave Infrared Cameras
Archives
- April 2024
- January 2024
- November 2023
- October 2023
- September 2023
- August 2023
- July 2023
- June 2023
- May 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- October 2020
- September 2020
- August 2020
- July 2020
- April 2020
- February 2020
- January 2020
- September 2019
- June 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- October 2018
- September 2018
- July 2018
- June 2018
- April 2018
- March 2018
- January 2018
- October 2017
- April 2017